What is Innoventric?
Innoventric is a specialized medical technology firm dedicated to the development of advanced transcatheter solutions for tricuspid regurgitation. By focusing on cross-caval technologies, the company addresses a critical gap in the treatment of structural heart disease, providing alternatives to traditional, high-risk surgical procedures. The organization is characterized by a deep commitment to clinical research and a robust patent portfolio, which serves as the foundation for its device development pipeline. Through its data-driven approach, Innoventric aims to broaden the accessibility of high-quality cardiac care, ensuring that a wider spectrum of patients can benefit from its innovative therapeutic interventions.
How much funding has Innoventric raised?
Innoventric has raised a total of $42.5M across 2 funding rounds:
Series A
$14M
Series B
$28.5M
Series A (2021): $14M, investors not publicly disclosed
Series B (2024): $28.5M led by RA Capital Management, BRM Capital, and The European Investment Council
Key Investors in Innoventric
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools.
BRM Capital
BRM Capital provides flexible funding solutions and working capital to help companies grow or turn around their businesses through a straightforward and efficient process.
The European Investment Council
The European Investment Council is a non-profit organization that fosters economic, commercial, and scientific connections, facilitating partnerships and supporting investment missions for companies seeking to enhance their growth processes.
What's next for Innoventric?
With the successful closure of its latest funding round, Innoventric is poised to transition from early-stage clinical validation to broader market adoption and operational scaling. The strategic focus will likely center on advancing its core device portfolio through regulatory milestones and expanding its clinical trial footprint to demonstrate long-term efficacy. Furthermore, the company is expected to leverage its strengthened balance sheet to enhance its manufacturing capabilities and commercial infrastructure. By maintaining its focus on evidence-based medical device innovation, Innoventric is set to solidify its position as a leader in the structural heart space, potentially attracting further interest from strategic partners and institutional investors as it moves toward commercialization.
See full Innoventric company page
